Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gen Ilac Veglik Urunlerinayi ve Ticaret ASIST:GENIL +0.64%87 Earnings Yield (Joel Greenblatt) % is 4.78% as of Mar. 2026, which is 8% above its 10-year median of 4.42. GuruFocus rates IST:GENIL with a GF Score™ of 87/100 and a GF Value™ of ₺8.24 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 1,010 Drug Manufacturers companies, Gen Ilac Veglik Urunlerinayi ve Ticaret AS ranks better than 63.07% on this metric.
IST:GENIL'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 0.14 Med: 4.42 Max: 14.77
Current: 5.41
During the past 8 years, the highest Earnings Yield (Joel Greenblatt) of Gen Ilac Veglik Urunlerinayi ve Ticaret AS was 14.77%. The lowest was 0.14%. And the median was 4.42%.
IST:GENIL's Earnings Yield (Joel Greenblatt) % is ranked better than 63.07% of 1010
companies
in the Drug Manufacturers industry
Industry Median: 3.325
vs IST:GENIL: 5.41
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 20.37%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS Earnings Yield (Joel Greenblatt) % Chart
Gen Ilac Veglik Urunlerinayi ve Ticaret AS Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Gen Ilac Veglik Urunlerinayi ve Ticaret AS's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gen Ilac Veglik Urunlerinayi ve Ticaret AS's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Gen Ilac Veglik Urunlerinayi ve Ticaret AS's Earnings Yield (Joel Greenblatt) % falls into.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Gen Ilac Veglik Urunlerinayi ve Ticaret AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺2,459 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 4.78% mean?
Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) has a Earnings Yield (Joel Greenblatt) % of 4.78% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Gen Ilac Veglik Urunlerinayi ve Ticaret AS and its competitors. This is near median its historical median of 4.42. Over the past decade, Gen Ilac Veglik Urunlerinayi ve Ticaret AS's Earnings Yield (Joel Greenblatt) % has ranged from 0.14 to 14.77. According to the industry distribution chart, Gen Ilac Veglik Urunlerinayi ve Ticaret AS ranks #373 out of 1010 companies in the Drug Manufacturers industry, placing it in the top 36.9%.
Is Gen Ilac Veglik Urunlerinayi ve Ticaret AS's Earnings Yield (Joel Greenblatt) % too high?
Gen Ilac Veglik Urunlerinayi ve Ticaret AS's current Earnings Yield (Joel Greenblatt) % of 4.78% is near median its 10-year median of 4.42. Over the past 10 years, this metric has ranged from a low of 0.14 to a high of 14.77. The Drug Manufacturers industry median Earnings Yield (Joel Greenblatt) % is 3.33. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's value of 4.78% is 43.8% above this industry median. Based on the distribution chart, Gen Ilac Veglik Urunlerinayi ve Ticaret AS ranks #373 out of 1010 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Gen Ilac Veglik Urunlerinayi ve Ticaret AS has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gen Ilac Veglik Urunlerinayi ve Ticaret AS's Earnings Yield (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Gen Ilac Veglik Urunlerinayi ve Ticaret AS ranks #373 out of 1010 companies for Earnings Yield (Joel Greenblatt) %. This puts Gen Ilac Veglik Urunlerinayi ve Ticaret AS in the upper half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 3.33. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's value of 4.78% is 43.8% above this benchmark. Historically, Gen Ilac Veglik Urunlerinayi ve Ticaret AS's own Earnings Yield (Joel Greenblatt) % has ranged from 0.14 to 14.77 over the past decade. While the company's 10-year median is 4.42 vs. the industry median of 3.33, Gen Ilac Veglik Urunlerinayi ve Ticaret AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.33, based on 1,010 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's current Earnings Yield (Joel Greenblatt) % of 4.78% is 43.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Gen Ilac Veglik Urunlerinayi ve Ticaret AS and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's current Earnings Yield (Joel Greenblatt) % is 4.78%, which is near median its own 10-year median of 4.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gen Ilac Veglik Urunlerinayi ve Ticaret AS stock overvalued right now?
Based on GuruFocus' analysis, Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) is currently considered Modestly Overvalued. The stock's GF Value™ is ₺8.24, compared to a current price of ₺9.38 — trading 13.8% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 4.78%, which is near median its 10-year median of 4.42 and 43.8% above the Drug Manufacturers industry median of 3.33. Gen Ilac Veglik Urunlerinayi ve Ticaret AS's overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL), the current Earnings Yield (Joel Greenblatt) % is 4.78% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gen Ilac Veglik Urunlerinayi ve Ticaret AS (IST:GENIL) Overvalued in 2026?
Based on GuruFocus' analysis, Gen Ilac Veglik Urunlerinayi ve Ticaret AS stock appears to be overvalued.
The current stock price of ₺9.38 is trading 13.8% above its estimated GF Value™ of ₺8.24.
GuruFocus considers Gen Ilac Veglik Urunlerinayi ve Ticaret AS to be Modestly Overvalued.
Key valuation signals for IST:GENIL:
Earnings Yield (Joel Greenblatt) %: 4.78% (near median its 10-year median of 4.42)
GF Value™: ₺8.24 vs. price of ₺9.38 (13.8% above fair value)
Industry Position: 43.8% above the Drug Manufacturers median (#373 of 1010)
No single metric tells the full story. See the IST:GENIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gen Ilac Ve Saglik Urunleri Sanayi ve Ticaret AS is a specialty pharmaceuticals company in Turkey. Its locally manufactured products include Cajex, Contra-K, Epamor, Genkort, Ilopera, among others, while imported products include AvonexPEN, Plegridy, Tecfidera, Regen-D among others.
87GF Score
Get the complete analysis for IST:GENIL
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:GENIL has been successfully added to your 
